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Lead author: JA Tan; kwak.ho@health.wa.gov.au Three part clinical question: Patients: Elective surgical adult intensive care unit (ICU) admissions with more than six hours sedation, and nonelective critically ill adult ICU admissions.
Intervention:
Sedation and analgesia provided by dexmedetomidine as compared to placebo or appropriate control. Outcome: Primary outcomes -length of ICU stay, duration of mechanical ventilation, risk of bradycardia and hypotension requiring intervention. Secondary outcomes -risk of delirium, self-extubation, atrial fibrillation, nausea and vomiting, myocardial infarction, hyperglycaemia, length of hospital stay and hospital mortality.
The study: A meta-analysis of available randomised controlled trials (RCTs).
Search terms: dexmedetomidine with analgesia, sedation or sedative agent and critically ill, trauma, sepsis, burns, ventilation, intensive care, critical care, cardiac surgery, heart surgery, valvular surgery or post-operative.
Data source: Two researchers searched three databases: the Cochrane controlled trial register (2009, issue 4) , EMBASE (January 1988 to 17 December 2009 ) and MEDLINE (1966 to 17 December 2009 as well as the websites of the International Network of Agencies of Health Technology Assessment in Health Care. The quality of the trials was assessed using an abstraction form considering allocation concealment, randomisation method, blinding of treatment, and inclusion and exclusion criteria. There was no disagreement between the researchers in data extraction or quality.
Study selection:
Inclusion criteria: randomised control trials comparing dexmedetomidine with a placebo, analgesic, or hypnotic agent in both elective post-operative and non-elective emergency critically ill patients. Most studies included concurrent analgesia and, on a number of occasions, extra sedation in both the intervention and control groups. Intervention group: dexmedetomidine infusion for sedation and analgesia.
Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients
A meta-analysis of randomised controlled trials comparing dexmedetomidine to control sedation showed weak evidence that dexmedetomidine might reduce length of intensive care unit (ICU) stay in certain critically ill patients, but the risk of bradycardia was significantly higher when using both a loading dose and high maintenance doses (>0.7 µg/kg/h). There was, however, a significant heterogeneity between trials reported.
Level of evidence: 1 ++ (Meta-analysis with a very low risk of bias)
Appraised by: S Clark, M Ezra Notes: *** = significant heterogeneity. Unless stated above there were no significant differences between strata.
CAT reviews
Control or placebo: saline or other hypnotic agent. Exclusion criteria: trials without defined end points, studies that replicated data already included, and those that used dexmedetomidine during the original surgery but not on ICU afterwards. The authors stratified the studies into those using dexmedetomidine as a sedative and analgesic agent after elective high-risk surgery and in non-elective critically ill patients. Additionally, the studies were also stratified into those which used loading dose and infusion rate greater than 0.7 μg/kg/h and those which did not use loading dose or infusion rate greater than 0.7 μg/kg/h. Relative risks were reported for categorical data and mean weighted differences for continuous data, with 95% confidence intervals (CI), using random effects modeling for both. Heterogeneity was assessed using I 2 . There was a significant level of heterogeneity between trials reported.
Data extraction: Thirty-two RCTs were identified. Eight were excluded for breeching the above exclusion criteria, leaving 24 RCTs (total of 2,419 patients). Fifteen studies looked at patients after high-risk elective surgery and nine studies comprised non-elective critically ill patients. Seven studies compared dexmedetomidine with placebo. Fifteen trials compared dexmedetomidine with an alternative hypnotic agent: propofol (10), midazolam (4), lorazepam (1). The remaining two studies compared dexmedetomidine with either morphine or haloperidol. The information on the primary outcomes was as follows: length of intensive care unit stay (11 studies with a total of 1,224 patients); duration of mechanical ventilation (11 studies with a total of 1,861 patients); bradycardia requiring intervention (10 studies with a total of 1,064 patients); and hypotension requiring intervention (12 studies with a total of 1,545 patients). The secondary outcomes had less information available except delirium (eight studies with a total of 1,754 patients) and hospital mortality (16 studies with a total of 1,839 patients).
EBM questions:
1. Do the methods allow for adequate testing of the hypotheses? Partially. Although this is a thorough and wellconsidered meta-analysis of the available randomised controlled trials that has made a valiant effort to combine the current trial data on dexmedetomidine as a sedation agent, the results are limited by a large variety of control groups and concurrent protocols leading to a significant level of heterogeneity between the studies. The overall quality of the studies was modest (13 studies had adequate allocation concealment, 12 studies were double blinded and only five had both adequate allocation concealment and double blinding). Additionally, little attention is paid to the question of dexmedetomidine' s analgesic properties except to note that nearly all patients required extra analgesia. 2. Do the statistical tests correctly test the results to allow differentiation of the statistically significant result? Yes. 3. Are the conclusions valid in light of the results? Yes. The authors concluded the following:
• The pooled studies showed a highly significant level of heterogeneity. • There was limited evidence that dexmedetomidine may reduce length of ICU stay, but they also point out that the difference becomes non-significant if the analysis is conducted only on double-blinded trials with adequate concealment. • Within the pooled studies, there was no significant increase in the incidence of bradycardias or hypotensive episodes requiring intervention. • However the incidence of bradycardia was higher when both a loading dose and high maintenance doses of dexmedetomidine were used. 4. Did results get omitted and why? No. 5. Did they suggest further areas for research? Yes. Implied in the discussion and stated explicitly at the end of the paper is need for further research that could define specific subgroups of patients who may benefit from the use of dexmedetomidine for sedation. There is a particular focus on its possible role in reducing delirium. 6. Did they make any recommendations based on the results and were they appropriate? No specific recommendations made. 7. Is the study relevant to my clinical practice? Yes, all intubated patients on ICU require at least some form of sedation with additional analgesia as necessary. There are a number of potential benefits to an agent that promotes natural sleep and does not produce respiratory depression. However, it should be noted that dexmedetomidine is not routinely used in the UK. 8. What level of evidence does this study represent? 1 ++ . 9. What grade of recommendation can I make on this result alone? A. 10. What grade of recommendation can I make when this study is considered along with other available evidence? A. 11. Should I change my practice because of these results? No. The results of this meta-analysis provide few conclusive reasons to switch hypnotic agents to dexmedetomidine. Additionally, there is an insufficient amount of data to effectively elucidate which subgroups might benefit the most from its use and further double blinded RCTs are needed. However, the study does suggest that dexmedetomidine has a comparable safety profile to other agents presently employed, and therefore may be worthy of consideration in appropriate patients.
Should I audit my current practice because of these results?
Yes. But only if your current protocol uses both a loading dose and high dose infusions, then it may be advisable to audit rate of bradycardic and hypotensive episodes that require intervention.
